Brasier Allan R, Zhao Yingxin, Wiktorowicz John E, Spratt Heidi M, Nascimento Eduardo J M, Cordeiro Marli T, Soman Kizhake V, Ju Hyunsu, Recinos Adrian, Stafford Susan, Wu Zheng, Marques Ernesto T A, Vasilakis Nikos
Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, United States; Sealy Center for Molecular Medicine, UTMB, United States; Institute for Translational Sciences, UTMB, United States.
Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, United States; Sealy Center for Molecular Medicine, UTMB, United States; Institute for Translational Sciences, UTMB, United States.
J Clin Virol. 2015 Mar;64:97-106. doi: 10.1016/j.jcv.2015.01.011. Epub 2015 Jan 17.
Dengue virus (DENV) infection is a significant risk to over a third of the human population that causes a wide spectrum of illness, ranging from sub-clinical disease to intermediate syndrome of vascular complications called dengue fever complicated (DFC) and severe, dengue hemorrhagic fever (DHF). Methods for discriminating outcomes will impact clinical trials and understanding disease pathophysiology.
We integrated a proteomics discovery pipeline with a heuristics approach to develop a molecular classifier to identify an intermediate phenotype of DENV-3 infectious outcome.
121 differentially expressed proteins were identified in plasma from DHF vs dengue fever (DF), and informative candidates were selected using nonparametric statistics. These were combined with markers that measure complement activation, acute phase response, cellular leak, granulocyte differentiation and viral load. From this, we applied quantitative proteomics to select a 15 member panel of proteins that accurately predicted DF, DHF, and DFC using a random forest classifier. The classifier primarily relied on acute phase (A2M), complement (CFD), platelet counts and cellular leak (TPM4) to produce an 86% accuracy of prediction with an area under the receiver operating curve of >0.9 for DHF and DFC vs DF.
Integrating discovery and heuristic approaches to sample distinct pathophysiological processes is a powerful approach in infectious disease. Early detection of intermediate outcomes of DENV-3 will speed clinical trials evaluating vaccines or drug interventions.
登革病毒(DENV)感染对超过三分之一的人类构成重大风险,可导致广泛的疾病,从亚临床疾病到称为登革热并发症(DFC)的血管并发症中间综合征以及严重的登革出血热(DHF)。区分结果的方法将影响临床试验和对疾病病理生理学的理解。
我们将蛋白质组学发现流程与启发式方法相结合,以开发一种分子分类器,用于识别DENV-3感染结果的中间表型。
在DHF与登革热(DF)患者的血浆中鉴定出121种差异表达蛋白,并使用非参数统计方法选择了信息丰富的候选蛋白。这些蛋白与测量补体激活、急性期反应、细胞渗漏、粒细胞分化和病毒载量的标志物相结合。据此,我们应用定量蛋白质组学,使用随机森林分类器选择了一个由15种蛋白质组成的蛋白组,该蛋白组能够准确预测DF、DHF和DFC。该分类器主要依靠急性期蛋白(A2M)、补体蛋白(CFD)、血小板计数和细胞渗漏蛋白(TPM4)进行预测,对于DHF和DFC与DF的区分,预测准确率达86%,受试者操作特征曲线下面积>0.9。
整合发现和启发式方法以区分不同的病理生理过程是传染病研究中的一种有效方法。早期检测DENV-3的中间结果将加快评估疫苗或药物干预措施的临床试验。